Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer
Identification of early-stage tumor and monitoring therapeutic efficacy and recurrence or metastasis of colorectal cancer (CRC) are urgently warranted for improving the outcome of CRC patients and reducing the disease-related mortality. In this study, we evaluated the diagnostic value of cell-free c...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2018-01-01
|
Series: | Disease Markers |
Online Access: | http://dx.doi.org/10.1155/2018/6437104 |
id |
doaj-bdefd38727544277858e4af6d0563d4a |
---|---|
record_format |
Article |
spelling |
doaj-bdefd38727544277858e4af6d0563d4a2020-11-24T22:54:34ZengHindawi LimitedDisease Markers0278-02401875-86302018-01-01201810.1155/2018/64371046437104Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal CancerBo Fu0Peng Yan1Shan Zhang2Yan Lu3Li Pan4Wenqiang Tang5Shen Chen6Shuangfeng Chen7Anqi Zhang8Wei Liu9Department of Central Laboratory, Liaocheng People’s Hospital, Liaocheng, ChinaDepartment of Gastroenterology, Liaocheng People’s Hospital, Liaocheng, ChinaDepartment of Gastroenterology, Liaocheng People’s Hospital, Liaocheng, ChinaDepartment of Gastroenterology, Liaocheng People’s Hospital, Liaocheng, ChinaDepartment of Central Laboratory, Liaocheng People’s Hospital, Liaocheng, ChinaDepartment of Central Laboratory, Liaocheng People’s Hospital, Liaocheng, ChinaDepartment of Breast and Thyroid Surgery, Liaocheng People’s Hospital, Liaocheng, ChinaDepartment of Central Laboratory, Liaocheng People’s Hospital, Liaocheng, ChinaDepartment of Central Laboratory, Liaocheng People’s Hospital, Liaocheng, ChinaDepartment of Central Laboratory, Liaocheng People’s Hospital, Liaocheng, ChinaIdentification of early-stage tumor and monitoring therapeutic efficacy and recurrence or metastasis of colorectal cancer (CRC) are urgently warranted for improving the outcome of CRC patients and reducing the disease-related mortality. In this study, we evaluated the diagnostic value of cell-free circulating methylated SEPT9 (mSEPT9) for CRC and beyond CRC and examined the potentiality of mSEPT9 in assessing therapeutic efficacy and monitoring recurrence of CRC. Our results confirmed the favorable diagnostic value of plasma mSEPT9 for CRC, with a sensitivity of 61.22% (95% confidence interval (CI): 51.33%–70.27%) and specificity of 93.7% (95% CI: 91.09%–95.57%) using 2/3 algorithm. The positive rate of mSEPT9 in CRC was correlated with tumor size, histological grade, and general histological type (P<0.05). Beyond CRC, gastric cancer patients also presented a high positive rate of plasma mSEPT9 (70%). The conversions between preoperative and postoperative plasma mSEPT9 reflected the therapeutic efficacy of curatively intended surgery for CRC patients. The persistent positivity of plasma mSEPT9 after surgery (within 7–14 days) was highly associated with impending recurrences or metastases (within one year), with a sensitivity of 100%. Postoperative mSEPT9 status during follow-up also provided valuable indication for CRC recurrence or metastases, with a good consistency (kappa = 0.818, P=0.001). Our results verified the reliability of plasma mSEPT9 as a biomarker for noninvasive diagnosis of CRC. More significantly, we revealed its valuable role in appraising CRC therapeutic efficacy and monitoring CRC recurrences or metastases. Further studies with larger sample sizes are needed to verify and elucidate the clinical utility of the promising findings.http://dx.doi.org/10.1155/2018/6437104 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bo Fu Peng Yan Shan Zhang Yan Lu Li Pan Wenqiang Tang Shen Chen Shuangfeng Chen Anqi Zhang Wei Liu |
spellingShingle |
Bo Fu Peng Yan Shan Zhang Yan Lu Li Pan Wenqiang Tang Shen Chen Shuangfeng Chen Anqi Zhang Wei Liu Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer Disease Markers |
author_facet |
Bo Fu Peng Yan Shan Zhang Yan Lu Li Pan Wenqiang Tang Shen Chen Shuangfeng Chen Anqi Zhang Wei Liu |
author_sort |
Bo Fu |
title |
Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer |
title_short |
Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer |
title_full |
Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer |
title_fullStr |
Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer |
title_full_unstemmed |
Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer |
title_sort |
cell-free circulating methylated sept9 for noninvasive diagnosis and monitoring of colorectal cancer |
publisher |
Hindawi Limited |
series |
Disease Markers |
issn |
0278-0240 1875-8630 |
publishDate |
2018-01-01 |
description |
Identification of early-stage tumor and monitoring therapeutic efficacy and recurrence or metastasis of colorectal cancer (CRC) are urgently warranted for improving the outcome of CRC patients and reducing the disease-related mortality. In this study, we evaluated the diagnostic value of cell-free circulating methylated SEPT9 (mSEPT9) for CRC and beyond CRC and examined the potentiality of mSEPT9 in assessing therapeutic efficacy and monitoring recurrence of CRC. Our results confirmed the favorable diagnostic value of plasma mSEPT9 for CRC, with a sensitivity of 61.22% (95% confidence interval (CI): 51.33%–70.27%) and specificity of 93.7% (95% CI: 91.09%–95.57%) using 2/3 algorithm. The positive rate of mSEPT9 in CRC was correlated with tumor size, histological grade, and general histological type (P<0.05). Beyond CRC, gastric cancer patients also presented a high positive rate of plasma mSEPT9 (70%). The conversions between preoperative and postoperative plasma mSEPT9 reflected the therapeutic efficacy of curatively intended surgery for CRC patients. The persistent positivity of plasma mSEPT9 after surgery (within 7–14 days) was highly associated with impending recurrences or metastases (within one year), with a sensitivity of 100%. Postoperative mSEPT9 status during follow-up also provided valuable indication for CRC recurrence or metastases, with a good consistency (kappa = 0.818, P=0.001). Our results verified the reliability of plasma mSEPT9 as a biomarker for noninvasive diagnosis of CRC. More significantly, we revealed its valuable role in appraising CRC therapeutic efficacy and monitoring CRC recurrences or metastases. Further studies with larger sample sizes are needed to verify and elucidate the clinical utility of the promising findings. |
url |
http://dx.doi.org/10.1155/2018/6437104 |
work_keys_str_mv |
AT bofu cellfreecirculatingmethylatedsept9fornoninvasivediagnosisandmonitoringofcolorectalcancer AT pengyan cellfreecirculatingmethylatedsept9fornoninvasivediagnosisandmonitoringofcolorectalcancer AT shanzhang cellfreecirculatingmethylatedsept9fornoninvasivediagnosisandmonitoringofcolorectalcancer AT yanlu cellfreecirculatingmethylatedsept9fornoninvasivediagnosisandmonitoringofcolorectalcancer AT lipan cellfreecirculatingmethylatedsept9fornoninvasivediagnosisandmonitoringofcolorectalcancer AT wenqiangtang cellfreecirculatingmethylatedsept9fornoninvasivediagnosisandmonitoringofcolorectalcancer AT shenchen cellfreecirculatingmethylatedsept9fornoninvasivediagnosisandmonitoringofcolorectalcancer AT shuangfengchen cellfreecirculatingmethylatedsept9fornoninvasivediagnosisandmonitoringofcolorectalcancer AT anqizhang cellfreecirculatingmethylatedsept9fornoninvasivediagnosisandmonitoringofcolorectalcancer AT weiliu cellfreecirculatingmethylatedsept9fornoninvasivediagnosisandmonitoringofcolorectalcancer |
_version_ |
1725659073931640832 |